Response to: “Minimum requirements for reporting clinical trials evaluating the therapeutic potential of platelet-rich plasma” - 05/12/20
Doi : 10.1016/j.jaad.2020.08.079
Lu Yin, BA a, ∗, Katerina Svigos, BA a, ∗, Kumar Sukhdeo, MD, PhD b, Anthony Ho, MD c, Kristen Lo Sicco, MD a, †, Jerry Shapiro, MD a, ⁎, † 
a The Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, New York
b OnDERMAND Dermatology, New York, New York
c Department of Dermatology, State University of New York Downstate Health Sciences University, Brooklyn, New York
∗Correspondence to: Jerry Shapiro, MD, 530 1st Ave #7R, New York, NY 10016530 1st Ave #7RNew YorkNY10016
El texto completo de este artículo está disponible en PDF.
| Funding sources: None. |
|
| Disclosure: Dr Shapiro is an investigator for RegenLab. Dr Lo Sicco is an investigator for RegenLab. Authors Yin and Svigos and Drs Sukhdeo and Ho have no conflicts of interest to declare. |
|
| IRB approval status: Not applicable. |
|
| Reprints not available from the authors. |
© 2020
American Academy of Dermatology, Inc.. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Vol 84 - N° 1
P. e45 - janvier 2021 Regresar al número
Artículo precedente
- Minimum requirements for reporting clinical trials evaluating the therapeutic potential of platelet-rich plasma
- Khan Sharun, Abhijit M. Pawde
- Variables affecting the potential efficacy of platelet-rich plasma in dermatology
- Khan Sharun, Abhijit M. Pawde
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?